2008至2023年病例级因果评估工具的范围综述:优势、不足与未来改进
国际药物警戒新进展工作组对2008至2023年开发或更新的病例级因果评估工具(CATs)进行范围综述,纳入48篇文章和7个灰色文献来源,识别出18个CATs。多数为算法类(67%),少数为混合类(22%)、全局判断类(6%)和概率类(6%)。部分工具针对特定结局或人群设计,未来可考虑纳入生物标志物以预测风险。
要点
- 共识别18个CATs,算法类占67%,混合类22%,全局判断和概率类各6%。
- 部分CATs针对特定结局(如药物性肝损伤、严重皮肤不良反应)或人群(儿科、新生儿ICU)设计。
- 未来改进方向包括纳入生物标志物、考虑药物质量、用药错误和依从性。
核心结论
- 现有CATs以算法类为主,针对特定结局或人群的工具可能受益于生物标志物的纳入。
研究设计与样本
- 国际药物警戒新进展工作组开展的范围综述,检索Embase和MEDLINE及灰色文献,纳入2008年1月1日至2023年12月31日期间开发或更新的CATs相关文献。
主要发现
- 共纳入48篇文章和7个灰色文献来源,识别出18个CATs。
- CATs分类:全局判断1个(6%),算法12个(67%),混合4个(22%),概率1个(6%)。
- 算法类CATs包括针对特定结局(严重皮肤不良反应1个,药物性肝损伤4个)或特定人群/环境(儿科1个,新生儿重症监护1个)的工具。
- 有1个CAT(WHO-AEFI)专为疫苗不良事件评估设计。
关键数值与推荐
- 针对药物性肝损伤和严重皮肤不良反应等结局的CATs,未来可能受益于纳入生物标志物作为风险预测因子。
- 对于免疫检查点抑制剂等特定生物制剂,生物标志物可能有助于识别免疫介导的不良反应。
- 因果评估还应考虑药物质量、潜在用药错误以及风险最小化措施的依从性评估。
临床怎么用
- 临床可根据特定治疗领域、临床环境或患者人群选择相应的CATs。
- 评估生物制剂相关不良反应时,可关注生物标志物的潜在作用。
- 因果评估需综合考量药物质量、用药错误和依从性等因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various approaches to causality assessment have been developed that generally fall into the following three categories; expert judgement/global introspection, algorithms or probabilistic/Bayesian methods (or a combination of these). Causality assessment tools (CATs) are designed to assess the likelihood that a medicine has caused an adverse event in a specific individual. OBJECTIVE: To provide an up-to-date assessment of existing CATs, the International Working Group on New Developments in Pharmacovigilance conducted a scoping review to identify CATs developed or updated between 2008 and 2023. The objective was to describe key components and strengths and weaknesses and to categorise CATs based on therapeutic area, clinical setting or patient population to support selection of the most appropriate tool within a specific context. We also discuss additional considerations for the assessment of adverse drug reactions seen with biologics. METHODS: Searches were conducted in Embase and MEDLINE and to identify relevant grey literature. Review articles that described CATs developed between 1 January, 2008 until 31 December, 2023 (including updates to pre-existing CATs) were included. The key components of each CAT identified were extracted in addition to its strengths, weaknesses and other performance characteristics. RESULTS: In total, 48 articles and 7 grey literature sources were eligible for inclusion; 18 CATs were identified, categorised as: global introspection (n = 1, 6%), algorithmic (n = 12, 67 %), hybrid (n = 4, 22%) and probabilistic (n = 1, 6 %). Algorithmic CATs included those for use in specific outcomes (severe cutaneous adverse reaction n = 1, drug-induced liver injury n = 4), or in specific populations/settings (paediatric n = 1, neonatal intensive care units n = 1). One CAT (World Health Organization tool for assessing adverse events following immunization, WHO-AEFI) was designed for use with vaccines. CONCLUSIONS: Causality assessment tools designed to assess certain outcomes, such as drug-induced liver injury and severe cutaneous adverse reaction, may benefit from the future inclusion of biomarkers as predictors of risk. For specific biologics, such as immune checkpoint inhibitors where there is a heightened risk of immune-mediated AEs, there may be a role for biomarkers to help identify immune checkpoint inhibitor-induced toxicity. Additional considerations for causality may include drug quality, potential for medication error and assessment of adherence to risk minimisation measures.
引用
- Cooper D, Ansari MT, Aurelius T, et al. A Scoping Review of Case-Level Causality Assessment Tools Developed Between 2008 and 2023; Strengths, Weaknesses and Potential Future Improvements. Drug Saf. 2026. PMID: 41910704. doi:10.1007/s40264-026-01665-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。